Genmab A/S (OTCPK:GNMSF) announces that a Phase 3 clinical trial, MAIA, evaluating licensee Janssen Biotech's (NYSE:JNJ) DARZALEX (daratumumab), combined with Celgene's (NASDAQ:CELG) REVLIMID (lenalidomide) and dexamethasone (DRd), compared to REVLIMID and dexamethasone alone (Rd) in newly diagnosed multiple myeloma patients who are not candidates for high-dose chemo and autologous stem cell transplant (ASCT) met the primary endpoint.
Preliminary results showed that DRd statistically significantly improved progression-free survival (PFS) with 45% less risk of cancer progression or death compared to patients receiving Rd (p<0.0001). Median PFS for the DRd group has not been reached versus 31.9 months for the Rd group.
The Independent Data Monitoring Committee has recommended releasing the data.
